Injectable drug administration specialist West Pharmaceutical Services has announced that Eric Green has been appointed the company's CEO, succeeding Dr. Donald Morel, Jr., Ph.D., current Chairman and CEO. Eric Green will join West and take on his new responsibilities on 24 April 2015.
Dr. Morel will serve as West's Chairman following Eric Green's appointment, until 1 July 2015, when he plans to formally retire.
Green joins West from Sigma-Aldrich Corporation, where he has served as Executive Vice President and President of the company's Research Markets business unit since 2013. In this role, Green served as a corporate officer and member of the senior executive team, with responsibility for managing a $1.4 billion business unit.
Green said: "I am excited and honoured to lead such a well-respected and successful company. I am impressed with West's track record for delivering both innovative packaging and integrated delivery solutions that play such a critical role in delivering injectable medicines for patients across the globe. I intend to build on the strategy the current management team has established, and partner with the Board to ensure West's continued success in the future."
Dr. Morel added: "Eric Green brings a wealth of leadership experience from his time with Sigma-Aldrich, a company that shares West's customer-centric approach to working with the pharmaceutical industry. He stood out among a very strong candidate list that was considered. We were particularly impressed with his track record of growing revenue and profit for the business units he has led; the diversity of his experience across different business segments, particularly in emerging markets; and his passion for leading people."